Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy

Chondrosarcoma is a common primary bone malignancy whose phenotype increases with its histologic grade. They are relatively resistant to chemotherapy and radiation therapy limiting curative options for disseminated disease. Chondroitin sulfate proteoglycan 4 (CSPG4) is a cell surface proteoglycan th...

Descripción completa

Detalles Bibliográficos
Autores principales: Nota, Sjoerd P. F. T., Osei-Hwedieh, David O., Drum, David L., Wang, Xinhui, Sabbatino, Francesco, Ferrone, Soldano, Schwab, Joseph H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468862/
https://www.ncbi.nlm.nih.gov/pubmed/36110930
http://dx.doi.org/10.3389/fonc.2022.939166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468862/
https://www.ncbi.nlm.nih.gov/pubmed/36110930
http://dx.doi.org/10.3389/fonc.2022.939166

Ejemplares similares